Wuxi AppTec reports 33.7% profit surge despite US scrutiny

Wuxi AppTec, Asia's leading contract pharmaceutical research firm, reported a remarkable 33.7% rise in net profit for the first half of 2026, driven by robust demand for weight-loss and diabetes treatments. The Shanghai-based company’s earnings far exceeded market expectations, defying challenges posed by US efforts to counter China’s biotech ambitions.

Earnings Outperform Market Projections

The company’s interim net profit attributable to shareholders soared to 11.08 billion yuan (US$1.64 billion), significantly surpassing Bloomberg’s consensus estimate of a 14.5% increase. This growth was fueled by strong commercial momentum across various client drug programmes, according to Li Ge, Wuxi AppTec's chairman and CEO. "We delivered strong growth across revenue, profit, and cash flow," Li stated in a release on Monday.

US Market Drives Revenue Growth

Sales in the United States, which accounted for 77% of Wuxi AppTec’s total revenue, surged to 22.28 billion yuan in the first half of 2026, up from 14.24 billion yuan during the same period last year. This robust performance in the US market underscores the company’s ability to maintain growth even as geopolitical tensions heighten scrutiny of Chinese biotech firms.

Stock Performance Reflects Investor Confidence

Wuxi AppTec’s Hong Kong-listed shares rose by 1.37% on Monday to HK$162.90, marking a year-to-date increase of approximately 62%. The broader Hang Seng Index, by comparison, gained 0.48% on the same day, highlighting the company’s standout performance in the market.

Why It Matters

Wuxi AppTec’s strong earnings come at a time when Chinese biotech companies face increasing scrutiny from the United States, as part of broader efforts to limit China’s technological and scientific advancements. The company’s ability to post record profits and expand its US business demonstrates resilience and underscores the global demand for its services, particularly in the fast-growing weight-loss and diabetes treatment sectors.

This performance not only solidifies Wuxi AppTec’s position as a leader in contract pharmaceutical research but also signals the continued interdependence of US and Chinese biotech industries despite geopolitical headwinds.

Source: South China Morning Post